MedTrace Logo

GSK BHR Study (Sont)

NCT00920543 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 464

Last updated 2016-09-01

No results posted yet for this study

Summary

The purpose of this study was to determine whether asthma control and reduced bronchial hyperresponsiveness could be achieved and maintained at a lower dose of inhaled corticosteroids with ADVAIR DISKUS twice-daily or FP twice-daily in adult and adolescent subjects with persistent asthma

Conditions

Interventions

DRUG

Placebo

Twice daily dosing

DRUG

FP 100mcg

Twice daily dosing

DRUG

FP 500mcg

Twice daily dosing

DRUG

FP 250mcg

Twice daily dosing

DRUG

FSC 100/50mcg

Twice daily dosing

DRUG

FSC 250/50mcg

Twice daily dosing

DRUG

FSC 500/50mcg

Twice daily dosing

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2004-10-31
Completion
2004-10-31

Countries

  • United States
  • Brazil
  • Latvia
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00920543 on ClinicalTrials.gov